Briefs: Eugia Pharma Specialities and Eugia SEZ
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Eugia Pharma Specialities restarts production at terminally sterilized product lines
The plant is yet to start commercial operations
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
Subscribe To Our Newsletter & Stay Updated